← Back to Home

Restoring Collagen in the Kidney: PS-003 Preclinical Results Announced for Alport Syndrome Gene Therapy

From human podocytes to mice and minipigs, PS-003 research is progressively validating the delivery and expression of the full-length COL4A5 gene. Purespring plans to submit an application for human trials in 2027, but there is no clinical evidence yet that it can preserve patients’ kidney function.

By SURL BioNews

The kidneys rely on a delicate basement membrane to filter blood. In patients with X-linked Alport syndrome, defects in the collagen that forms this structure can lead to progressive kidney damage. On October 27, Purespring Therapeutics announced preclinical results for its gene therapy PS-003, which aims to enable kidney cells to produce the missing protein again, providing experimental support for a treatment strategy that addresses the genetic defect.

The research was presented at the American Society of Nephrology (ASN) Kidney Week 2026. According to the official abstract, PS-003 uses dual adeno-associated virus (AAV) vectors to deliver the full-length COL4A5 gene into podocytes through the GlomThera platform. These cells help maintain the glomerular filtration barrier. The large size of the COL4A5 sequence and the difficulty of precisely targeting delivery to podocytes have long posed two hurdles in development.

In experiments with human podocytes, the COL4A5 protein produced by PS-003 could assemble with COL4A3 and COL4A4 to form and secrete collagen heterotrimers—structures made up of three different protein chains. This takes the evidence a step further: the protein produced by the cells was capable of assembly, rather than gene expression merely being detectable.

Animal studies separately examined the feasibility of protein restoration and delivery. In the G5X mouse model of Alport syndrome, the research team used a mouse surrogate version of PS-003, restoring COL4A5 in the glomeruli and stabilizing the COL4A3 and COL4A4 proteins. Experiments in Göttingen minipigs also confirmed through molecular testing that surrogate vectors could reconstitute the full-length COL4A5 gene in the kidneys and produce signals of gene expression. These results still cannot be directly equated with improved kidney function in patients.

Regarding safety, the ASN abstract reported that toxicology and histopathology assessments in treated animals found no treatment-related concerns. However, low levels of transcripts were still detected in the liver, spleen, and pancreas, indicating that expression was not entirely restricted to the kidneys. The abstract did not provide the full animal numbers, follow-up duration, or quantitative efficacy data, leaving insufficient evidence to assess long-term risks or how long any treatment benefit might last.

Another study presented at the same meeting focused on patients who may remain unidentified. According to the company’s October 14 preview and subsequent announcement, the team analyzed more than 1.2 million genomes, covering data from the United States, the United Kingdom, Europe, and Japan. It noted that the G624D variant, which is associated with later disease onset, may suggest that genetic testing remains insufficient among older patients with suspected disease. This population analysis helps characterize the disease, but it cannot establish that everyone carrying the relevant variants is suitable for PS-003.

Purespring plans to submit an investigational new drug (IND) application for PS-003 in 2027 in preparation for a first-in-human study. The current findings primarily address early questions, such as whether the gene can be delivered and whether the protein can assemble. Whether the therapy can slow kidney function decline, which patients it may suit, and its safety and durability in humans remain to be clarified in clinical trials.

References

  1. Purespring Therapeutics
  2. American Society of Nephrology
  3. Purespring Therapeutics